Zacks Research Issues Positive Outlook for Bruker Earnings

Bruker Co. (NASDAQ:BRKR - Free Report) - Equities researchers at Zacks Research increased their Q4 2025 earnings per share estimates for shares of Bruker in a report released on Wednesday, May 28th. Zacks Research analyst R. Department now forecasts that the medical research company will earn $0.91 per share for the quarter, up from their prior estimate of $0.88. The consensus estimate for Bruker's current full-year earnings is $2.69 per share. Zacks Research also issued estimates for Bruker's Q1 2026 earnings at $0.48 EPS, Q2 2026 earnings at $0.50 EPS, FY2026 earnings at $2.61 EPS, Q1 2027 earnings at $0.64 EPS and FY2027 earnings at $3.05 EPS.

Bruker (NASDAQ:BRKR - Get Free Report) last issued its quarterly earnings results on Wednesday, May 7th. The medical research company reported $0.47 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.46 by $0.01. Bruker had a return on equity of 21.01% and a net margin of 3.36%. The business had revenue of $801.40 million during the quarter, compared to analyst estimates of $763.83 million. During the same quarter in the prior year, the business posted $0.53 EPS. Bruker's revenue for the quarter was up 11.0% compared to the same quarter last year.

A number of other research analysts also recently commented on the company. Citigroup downgraded Bruker from a "strong-buy" rating to a "hold" rating and lowered their target price for the company from $50.00 to $40.00 in a research report on Thursday, May 22nd. Guggenheim reiterated a "buy" rating on shares of Bruker in a research note on Monday, February 24th. UBS Group decreased their price target on shares of Bruker from $57.00 to $45.00 and set a "neutral" rating for the company in a research note on Thursday, May 8th. Wells Fargo & Company reduced their price objective on shares of Bruker from $75.00 to $60.00 and set an "overweight" rating for the company in a research note on Thursday, April 17th. Finally, Stifel Nicolaus dropped their price objective on Bruker from $57.00 to $48.00 and set a "hold" rating on the stock in a research report on Thursday, May 8th. Six equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus target price of $59.10.

Bruker Price Performance

Shares of BRKR traded down $0.08 during midday trading on Friday, hitting $36.62. 712,030 shares of the company traded hands, compared to its average volume of 1,609,387. The company has a debt-to-equity ratio of 1.15, a quick ratio of 0.77 and a current ratio of 1.60. The stock has a market cap of $5.55 billion, a price-to-earnings ratio of 48.23, a PEG ratio of 2.16 and a beta of 1.23. Bruker has a 52 week low of $34.10 and a 52 week high of $72.94. The firm has a 50 day moving average of $38.62 and a 200-day moving average of $48.92.

Bruker Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 27th. Stockholders of record on Monday, June 16th will be issued a dividend of $0.05 per share. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.55%. The ex-dividend date of this dividend is Monday, June 16th. Bruker's dividend payout ratio (DPR) is presently 38.46%.

Institutional Investors Weigh In On Bruker

A number of large investors have recently made changes to their positions in the stock. Pinnacle Bancorp Inc. purchased a new stake in Bruker in the first quarter valued at $29,000. Allworth Financial LP raised its position in shares of Bruker by 92.4% during the 1st quarter. Allworth Financial LP now owns 758 shares of the medical research company's stock worth $30,000 after purchasing an additional 364 shares during the last quarter. Caitong International Asset Management Co. Ltd raised its position in shares of Bruker by 1,354.5% during the 1st quarter. Caitong International Asset Management Co. Ltd now owns 800 shares of the medical research company's stock worth $33,000 after purchasing an additional 745 shares during the last quarter. Annis Gardner Whiting Capital Advisors LLC acquired a new position in shares of Bruker during the 1st quarter worth about $42,000. Finally, MassMutual Private Wealth & Trust FSB raised its holdings in Bruker by 274.9% in the 1st quarter. MassMutual Private Wealth & Trust FSB now owns 1,091 shares of the medical research company's stock valued at $46,000 after acquiring an additional 800 shares during the last quarter. 79.52% of the stock is owned by hedge funds and other institutional investors.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.